TaiMed Biologics to Present HIV Therapy Data at IDWeek 2026
News related to:TaiMed Biologics · 1 min read
TAIPEI, Taiwan, Oct. 13, 2026 /CourierPR/ -- TaiMed Biologics, a commercial-stage biologics company based in Taiwan, is set to present key findings at the upcoming 2026 IDWeek Annual Meeting, which will take place from October 21 to 24 in Washington, D.C. The presentations will focus on the company's lead clinical-stage long-acting maintenance therapy candidate, TMB-365, and its combination with TMB-380.
At the meeting, TaiMed Biologics will deliver an oral presentation on the single-dose escalation study of TMB-365. The study, led by Martin Markowitz, the company's Acting Medical Director, will explore the safety, pharmacokinetics, and antiviral activity of TMB-365 in people living with HIV. This presentation is scheduled for October 23, 2026, from 2:45 PM to 2:57 PM Eastern Time in room 103 AB.
Additionally, TaiMed Biologics will present a poster on the TMB-365 and TMB-380 combination regimen. The poster, also authored by Markowitz, will delve into the potential of this regimen as a standalone maintenance therapy for people living with HIV-1 who are on combination antiretroviral therapy. This presentation is set for October 22, 2026, from 12:15 PM to 1:30 PM in the Poster Hall B-C.
Jimmy Chang, PhD, Chief Executive Officer of TaiMed Biologics, emphasized the significance of these studies.
Founded in 2007, TaiMed Biologics is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company has already achieved significant milestones, including the development of ibalizumab (Trogarzo®), the first monoclonal antibody approved by the U.S. FDA for the treatment of HIV-1. With the ongoing research and development of TMB-365 and TMB-380, the company continues to advance HIV care.
The presentations at IDWeek 2026 are expected to generate valuable discussions among the infectious diseases community, which is central to TaiMed Biologics' mission. The company looks forward to sharing its findings and engaging in meaningful dialogue with healthcare professionals and researchers.